Lecanemab reduces brain amyloid-β and delays cognitive worsening

David S. Knopman

doi:10.1016/j.xcrm.2023.100982

Lecanemab reduces brain amyloid-β and delays cognitive worsening

David S. Knopman

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.

Original language	English (US)
Article number	100982
Journal	Cell Reports Medicine
Volume	4
Issue number	3
DOIs	https://doi.org/10.1016/j.xcrm.2023.100982
State	Published - Mar 21 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.xcrm.2023.100982

Cite this

@article{aa329683dd024b0fbf6e29b44b48b04f,

title = "Lecanemab reduces brain amyloid-β and delays cognitive worsening",

abstract = "Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.",

author = "Knopman, {David S.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = mar,

day = "21",

doi = "10.1016/j.xcrm.2023.100982",

language = "English (US)",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Lecanemab reduces brain amyloid-β and delays cognitive worsening

AU - Knopman, David S.

PY - 2023/3/21

Y1 - 2023/3/21

N2 - Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.

AB - Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.

UR - http://www.scopus.com/inward/record.url?scp=85150275679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150275679&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.100982

DO - 10.1016/j.xcrm.2023.100982

M3 - Comment/debate

C2 - 36948153

AN - SCOPUS:85150275679

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 3

M1 - 100982

ER -

Lecanemab reduces brain amyloid-β and delays cognitive worsening

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this